Tic10

RPMI1640 medium and penicillin‐streptomycin were purchased from Wako Pure Chemical Industries, Ltd (Osaka, Japan). FBS was obtained from Nichirei Biosciences Inc. (Tokyo, Japan). MTT was obtained from Sigma‐Aldrich (St. Louis, MO). Akt inhibitors afuresertib, Akti‐1/2, AZD5363, GSK690693, ipatasertib (GDC‐0068), MK‐2206, perifosine, PHT‐427, and TIC10 and PDPK1 inhibitor OSU‐03012 were obtained from Selleck Chemicals (Houston, TX). Propidium iodide (PI) was obtained from Merck Millipore (Billerica, MA). Annexin V (AxV)–FITC was obtained from MBL (Nagoya, Japan). All antibodies used in this study were purchased from Cell Signaling Technology Inc. (Beverly, MA).

Primary antibodies against phospho-AKT (S473), pan-AKT, phospho-FoxO3a (S253), totalFoxO3a, phospho-p65 (S276), total-p65, cleaved-caspase3, cleaved-caspase1, cleaved-PARP1, LC3 and p62 were purchased from Cell Signaling Technology (Boston, Massachusetts, USA), total-caspase3, PAR and p-MLKL(S358) was purchased from abcam (Cambridge, UK), p53, PARP1, AIF, pan-AKT, totalFoxO3a, total-p65, GPX4 and β-actin were purchased from proteintech (Wuhan, Hubei, China), Cox IV, H3 and HRP conjugated anti-rabbit/mouse secondary antibodies were purchased from Abbkine (Wuhan, Hubei, China). Lipofectamine 2000 was purchased from Thermo Fisher Scientific (Waltham, Massachusetts, USA). AKT inhibitor SC66, TIC10, autophagy inhibitor CQ, ULK101, pan-caspase inhibitor Z-VAD-FMK and PARP1 inhibitor 3AB were purchased from Selleck (Houston, Texas, USA). CCK-8 kit was from 7 Sea Biotech (Shanghai, China). ROS inhibitor NAC was purchased from Topscience (Shanghai, China).